Literature DB >> 3948457

Corticosteroid therapy-induced obesity in children.

R J Merritt, S L Hack, M Kalsch, D Olson.   

Abstract

The severity and persistence of corticosteroid-induced obesity were evaluated retrospectively in 23 children aged 1-14 yrs requiring more than 60 days of therapy with prednisone for idiopathic nephrotic syndrome. Mean relative weight (after clearing of proteinuria) at initiation of therapy was 107 +/- 10 percent. Peak relative weight on therapy was 119 +/- 15 percent following a mean total of 31 months of cumulative steroid therapy. The most recent available relative weight in remission at least 6 months following cessation of therapy was 107 +/- 18 percent. The number of children whose relative weight exceeded 120 percent at initiation of, during and following therapy was 3, 10, and 4, respectively. In those with normal initial relative weight (less than 110%) there was no persistent obesity. Two of three initially obese patients (relative weight greater than 120%) remained obese. All patients with persistent obesity following therapy had initial relative weight of at least 110 percent and peak relative weight of more than 130 percent. The risk of persistent obesity as a result of chronic corticosteroid therapy in initially normal weight children who do not exceed 130 percent relative weight during therapy appears to be small.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3948457     DOI: 10.1177/000992288602500304

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  9 in total

1.  Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome.

Authors:  Akio Nakamura; Ryo Niimi; Kumiko Kurosaki; Yukishige Yanagawa
Journal:  Clin Exp Nephrol       Date:  2010-07-17       Impact factor: 2.801

2.  Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome.

Authors:  Bethany J Foster; Justine Shults; Babette S Zemel; Mary B Leonard
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

3.  Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.

Authors:  Bo Zheng; Xiang-Qing Yu; Warren Greth; Gabriel J Robbie
Journal:  Br J Clin Pharmacol       Date:  2016-03-04       Impact factor: 4.335

4.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy.

Authors:  Yoshitsugu Kaku; Yasufumi Ohtsuka; Yasuhiro Komatsu; Toshiyuki Ohta; Takuhito Nagai; Hiroshi Kaito; Shuji Kondo; Yohei Ikezumi; Seiji Tanaka; Shinsuke Matsumoto; Mayumi Sako; Kazushi Tsuruga; Koichi Nakanishi; Koichi Kamei; Hiroshi Saito; Shuichiro Fujinaga; Yuko Hamasaki; Hiroko Chikamoto; Kenji Ishikura; Kazumoto Iijima
Journal:  Clin Exp Nephrol       Date:  2015-02       Impact factor: 2.801

5.  Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases.

Authors:  Natalie J Shiff; Rollin Brant; Jaime Guzman; David A Cabral; Adam M Huber; Paivimm Miettunen; Johannes Roth; Rosie Scuccimarri; Nathalie Alos; Stephanie A Atkinson; Jean Paul Collet; Robert Couch; Elizabeth A Cummings; Peter B Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Bianca Lang; Maggie Larche; Claire Leblanc; Celia Rodd; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Frank Rauch; Leanne M Ward
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-01       Impact factor: 4.794

Review 6.  Bodyweight change as an adverse effect of drug treatment. Mechanisms and management.

Authors:  H Pijl; A E Meinders
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

7.  Impact of rituximab on height and weight in children with refractory steroid-dependent nephrotic syndrome.

Authors:  Mai Sato; Shuichi Ito; Masao Ogura; Koichi Kamei
Journal:  Pediatr Nephrol       Date:  2014-03-07       Impact factor: 3.714

Review 8.  Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children.

Authors:  Fahad Aljebab; Imti Choonara; Sharon Conroy
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

Review 9.  The non-immunosuppressive management of childhood nephrotic syndrome.

Authors:  James McCaffrey; Rachel Lennon; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2015-11-10       Impact factor: 3.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.